Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects With Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02795832
Recruitment Status : Completed
First Posted : June 10, 2016
Results First Posted : April 5, 2019
Last Update Posted : April 5, 2019
Sponsor:
Information provided by (Responsible Party):
Ziarco Pharma Ltd

Brief Summary:
A Randomised, Adaptive Design, Double-Blind (3rd Party Open), Placebo Controlled, Sequential Group Study to Determine the Safety,Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of a Topical ZPL-5212372 (1.0% w/w) Ointment Administered for up to 2 Weeks in Adult Healthy Volunteers and Patients with Moderate to Severe Atopic Dermatitis

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: ZPL-5212372 1% w/w Ointment BID Drug: Placebo Ointment BID Phase 1 Phase 2

Detailed Description:

This study was a randomised, adaptive design, double blind (3rd party open), placebo controlled, sequential group study in both healthy volunteers and patients with moderate to severe AD. This study was divided into 3 separate, sequential cohorts:

  • Cohort 1 were to assess safety, toleration and pharmacokinetics (PK) with intensive monitoring as in-patients over 7 days of dosing in healthy volunteers.
  • Cohort 2 were to assess safety, toleration and PK with intensive monitoring as in-patients over 7 days of dosing in moderate to severe AD patients.
  • Cohort 3 were to assess efficacy, safety, toleration and PK as out-patients over 14 days of dosing in moderate to severe AD patients.

Subjects received 1.0% (w/w) ZPL-5212372 or matched placebo ointment topically, twice daily.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo Controlled Study to Determine the Safety, Pharmacokinetics and Efficacy of Topical ZPL-5212372 Ointment Administered BID for up to 2 Weeks in Healthy Subjects and Subjects With Atopic Dermatitis.
Study Start Date : June 2016
Actual Primary Completion Date : March 1, 2017
Actual Study Completion Date : March 1, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Experimental: Cohort 1a
ZPL-5212372 1% w/w Ointment BID
Drug: ZPL-5212372 1% w/w Ointment BID
Placebo Comparator: Cohort 1b
Placebo Ointment BID
Drug: Placebo Ointment BID
Experimental: Cohort 2a
ZPL-5212372 1% w/w Ointment BID
Drug: ZPL-5212372 1% w/w Ointment BID
Placebo Comparator: Cohort 2b
Placebo Ointment BID
Drug: Placebo Ointment BID
Experimental: Cohort 3a
ZPL-5212372 1% w/w OIntment BID
Drug: ZPL-5212372 1% w/w Ointment BID
Placebo Comparator: Cohort 3b
Placebo Ointment BID
Drug: Placebo Ointment BID



Primary Outcome Measures :
  1. Percent Change From Baseline in EASI Score in Cohort 3 [ Time Frame: Day 1 and Day 14 ]
    The EASI is a validated tool used to measure the severity and extent of atopic eczema (Eczema Area and Severity Index). The body is divided into 4 sections of total skin area: head including neck (10%); arms including extremities (20%); trunk (30%) and legs including extremities (40%). Each area is scored and the 4 scores are combined into the final EASI. The severity parameters are measured on a scale of 0 to 3 (from none to severe). For each section, the percentage area of skin involved with eczema is estimated and transformed into an extent grade from 0 to 6, from 0% of involved skin area with eczema to 90-100% of involved skin area with eczema. The sum of all four severity parameters is calculated for each section of skin and then multiplied by the weight of the respective section. This value is then multiplied by the extent score for that body area. The EASI value can range from 0-72, a higher score indicates more severe disease.

  2. Percent Change From Baseline in EASI Score Over Time in Cohort 3 - Observed Case [ Time Frame: Days 1, 5, 8, 10, and 15 ]
    The EASI is a validated tool used to measure the severity and extent of atopic eczema (Eczema Area and Severity Index). The body is divided into 4 sections of total skin area: head including neck (10%); arms including extremities (20%); trunk (30%) and legs including extremities (40%). Each area is scored and the 4 scores are combined into the final EASI. The severity parameters are measured on a scale of 0 to 3 (from none to severe). For each section, the percentage area of skin involved with eczema is estimated and transformed into an extent grade from 0 to 6, from 0% of involved skin area with eczema to 90-100% of involved skin area with eczema. The sum of all four severity parameters is calculated for each section of skin and then multiplied by the weight of the respective section. This value is then multiplied by the extent score for that body area. The EASI value can range from 0-72, a higher score indicates more severe disease.


Secondary Outcome Measures :
  1. Summary of EASI-50 and EASI-75 Responders at Week 2 - Cohort 3 [ Time Frame: Day 14 ]

    The proportion of subjects who achieved EASI-50 and EASI-75 responses at Week 2 were compared between treatment groups.

    EASI-50 was defined as a ≥50% reduction from baseline in EASI score at Week 2. EASI-75 was defined as a ≥75% reduction from baseline in EASI score at Week 2.


  2. Percentage of Responders on Investigators Global Assessment in Cohort 3 [ Time Frame: Day 14 ]

    The following secondary endpoints were assessed for IGA:

    A subject was considered as having IGA success if they achieved a score of 'Clear' or 'Almost clear'; note, as subjects required a score of ≥3 to enter the study they must have had a reduction of ≥2 from baseline to achieve success A subject was considered as having an IGA response if they achieved a score of 'Clear' or 'Almost clear', or a reduction of ≥2 from baseline IGA was summarized for the FAS with counts and percentages by treatment at each visit.


  3. Change From Baseline in NRS for Pruritus at Week 2 - Observed Case in Cohort 3 [ Time Frame: Day 1 to day 14 ]

    Numerical Rating Scale (NRS) for Pruritus (worst itch). The Pruritus NRS is an assessment tool that will be used to assess the subject's worst itch as a result of AD in the previous 24 hours.

    They will be asked the following question:

    On a scale of 0 (No Itching) to 10 (Itching as bad as you can imagine), please rate the WORST itching that you felt over the last 24 hours.


  4. Summary of Patient Global Impression of Change and Logistic Regression of Patient Global Impression of Change in Cohort 3 [ Time Frame: End of treatment (day 15) ]

    Patient Global Impression of Change (PGIC) The PGIC scores were summarised for the FAS with counts and percentages in each treatment group. All data collected were included.

    The PGIC was dichotomized into responders, defined as responses of 'Very Much Improved', 'Much Improved' or 'Minimally improved' and non-responders (all other responses plus missing data).


  5. Change From Baseline in Body Surface Area at Week 2 - Observed Case in Cohort 3 [ Time Frame: Day 1 to day 14 ]
    Body Surface Area (BSA). The percentage BSA affected was summarised at each visit, including change from baseline, by treatment group, using the Full Analysis Set.


Other Outcome Measures:
  1. ZPL-5212372 Cmax for Patients in Cohort 2 [ Time Frame: Day 1, Day 7 ]
    PK parameters for patients who had ointment applied over 40% BSA.

  2. ZPL-5212372 AUCt for Patients in Cohort 2 [ Time Frame: Day 1, Day 7 ]
    PK parameters for patients who had ointment applied over 40% BSA.

  3. ZPL-5212372 Trough Plasma Concentrations in Cohort 3 [ Time Frame: Day 5, Day 8, Day 10, Day 15 ]
    PK parameters for patients who had ointment applied over 40% BSA.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy males or females, aged between 18 and 55 years, inclusive (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).

or

Males and females aged 18-65 years inclusive with physician documented history or diagnosis of atopic dermatitis for at least 6 months prior to screening. AD should be diagnosed by the Eichenfield revised criteria of Hanifin and Rajka.

For Atopic Dermatitis Patients:

Eczema Area and Severity Index (EASI) of ≥9 and <48 at Screening and an EASI of ≥12 and <48 at Day 1.

An Investigator's Global Assessment (IGA) score ≥ 3 at both Screening and Day 1.

Atopic dermatitis affecting between ≥10 to <40% BSA at Screening and ≥10% to <50% BSA on Day 1.

All Subjects:

Evidence of a personally signed and dated informed consent form, indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion Criteria:

For Healthy Subjects

  • Evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • Have tattoos covering areas of skin to be dosed with study ointment.
  • Subjects who are hirsute in areas of skin to be dosed with study ointment.
  • Subjects who have received treatment with an investigational drug within 3 months prior to screening.

For Atopic Dermatitis Patients:

  • AD of such severity (EASI >48) that the subject could not comply with the demands of the study and/or the subject is not a suitable candidate for a placebo-controlled study.
  • Have concomitant skin disease or infection (e.g. acne, impetigo) or presence of skin comorbidities in the study area to be dosed that may interfere with study assessments.
  • Have received phototherapy (e.g. UVA, UVB or PUVA therapy), or systemic therapy (e.g. immunosuppressants [such as cyclosporine, azathioprine, methotrexate], cytostatics) known or suspected to have an effect on AD, within 4 weeks of the start of the study. All other biologics should not have been used within 3 months of the start of study.
  • Have received systemic corticosteroids (e.g. oral, intravenous, intraarticular, rectal) within 4 weeks of the start of the study. Subjects on a stable maintenance dose (over the preceding 3 months) of inhaled or intranasal CS may participate.
  • Patients treated with oral antihistamines or topical calcineurin inhibitors or topical steroids within 7 days of starting study; intranasal antihistamines for the treatment of allergic rhinitis are acceptable.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02795832


Locations
Layout table for location information
United Kingdom
MAC
Blackpool, United Kingdom
MAC
Leeds, United Kingdom
MAC
Manchester, United Kingdom
Sponsors and Collaborators
Ziarco Pharma Ltd
Investigators
Layout table for investigator information
Study Director: Anne Parneix, MD Novartis
  Study Documents (Full-Text)

Documents provided by Ziarco Pharma Ltd:
Statistical Analysis Plan  [PDF] March 16, 2017
Study Protocol  [PDF] July 28, 2016

Layout table for additonal information
Responsible Party: Ziarco Pharma Ltd
ClinicalTrials.gov Identifier: NCT02795832    
Other Study ID Numbers: Ziarcopharma
First Posted: June 10, 2016    Key Record Dates
Results First Posted: April 5, 2019
Last Update Posted: April 5, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases